[Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
The article summarizes current knowledge about the possibilities for influencing the cardiovascular risk in treatment of type 2 diabetes, especially focusing on the results of a prospective morbidity-mortality LEADER trial, which demonstrated the superiority of liraglutide in patients with very high cardiovascular risk.


BACKGROUND
cardiovascular risk - LEADER - liraglutid - type 2 diabetes mellitus.
Jindřich
J
Olšovský
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide / Q000627:therapeutic use*; D012307:Risk Factors
D007004:Hypoglycemic Agents; D000069450:Liraglutide